OX40 levels distinguished DIHS/DRESS from other inflammatory dermatologic conditions, and were associated with HHV-6 reactivation
HHV-6 as a trigger for chronic fatigue syndrome: a meta-analysis
Systematic review and meta-analysis confirm an association, but not a causal link, between HHV-6 and CFS
Viral reactivation may be one cause of febrile neutropenia in chemotherapy patients
HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients
A relationship between human endogenous retroviruses and HHV-6A/B in multiple sclerosis patients
Significant positive correlations were found between HERV family proteins and antibodies to HHV-6A/B but not antibodies to EBV
The U20 and U21 genes of HHV-6A downregulate NK cell attack
U20/21 genes may help HHV-6A evade immune response
CMV infection may diminish the risk of developing MS
Studies conducted on serum obtained before development of MS indicate possible protective role
HHV-6 miRNA inhibits host miRNA to trigger reactivation from latency
A viral miRNA disrupts mitochondrial architecture, suppresses type I interferon production, is necessary for productive infection and for virus reactivation, all by inhibiting multiple members of the host miR-30 family—creating a therapeutic target to suppress reactivation.
Seronegative pediatric liver transplant patients frequently acquire clinically significant HHV-6 infections from the donor liver or accompanying leucocytes
HHV-6 seronegativity pre-transplantation predicts HHV-6 viremia post-transplantation
4C-seq genomic methodology used to examine HHV-6A integration sites
Chromatin interactions help silence transcription of HHV-6A genes following integration
The effects of HHV-6B infection on immune checkpoint inhibition
HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways
Breakthrough reactivation of HHV-6 occurs with liver transplantation in spite of valganciclovir preemptive therapy for CMV
High-grade HHV-6 viremia is independently associated with rejection of liver transplants within 12 months
Adult patients with lower levels of anti-HHV-6 IgG are significantly more likely to experience HHV-6 reactivation following cord blood transplant
Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation
The importance of individual glycoprotein components of the HHV-6A/6B envelope tetramer on essential viral functions
The combination of gQ1 and gQ2 tetramer components of both HHV-6A/6B are important for viral propagation, probably by affecting attachment to their different receptors.
Reactivation of herpesviruses demonstrated in severely ill patients with acute COVID-19
EBV, CMV, and HHV-6 reactivation were found in a small cohort of severe COVID-19 patients
Quantitative PCR of serum found superior to whole blood in differentiating between latent virus and viremia following cord blood transplantation
Use of serum more easily distinguishes viremia from latent virus